0001193125-22-085150.txt : 20220325 0001193125-22-085150.hdr.sgml : 20220325 20220325161007 ACCESSION NUMBER: 0001193125-22-085150 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220325 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220325 DATE AS OF CHANGE: 20220325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 22771451 BUSINESS ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 d262323d8k.htm 8-K 8-K
false 0001706431 0001706431 2022-03-25 2022-03-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2022

 

 

Vir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39083   81-2730369
(State or other jurisdiction
of incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification No.)

 

499 Illinois Street, Suite 500    
San Francisco, California     94158
(Address of principal executive offices)     (Zip Code)

Registrant’s telephone number, including area code: (415) 906-4324

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value   VIR   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events.

On March 25, 2022, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has amended the Emergency Use Authorization (“EUA”) Fact Sheet for sotrovimab, an investigational monoclonal antibody. The FDA has determined that, based on the totality of available evidence, including new live virus data generated by the Company, it is unlikely that the sotrovimab 500 mg dose will be effective against the Omicron BA.2 variant. The Company and GlaxoSmithKline (“GSK”) are preparing a package of data in support of a higher dose of sotrovimab for the Omicron BA.2 subvariant and will be sharing these data with regulatory and health authorities around the world for discussion. The FDA has updated its website to exclude sotrovimab use in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information, including variant susceptibility to these drugs and regional variant frequency (HHS regions 1 and 2). A copy of the press release is filed as Exhibit 99.1 and is incorporated herein by reference. In connection with this announcement, the Company is providing the following additional information:

 

  •  

The Company still expects to recognize approximately $1.1 billion of sotrovimab collaboration revenues when sotrovimab doses are delivered in the first half of 2022.

 

  •  

The Company and GSK still expect to manufacture approximately 2 million doses in the first half of 2022 and additional doses in the second half of 2022.

 

  •  

The Company and GSK still plan to submit a Biologics License Application for sotrovimab to the FDA in the second half of 2022.

 

  •  

The Company and GSK still expect to commence two Phase 3 trials in the second quarter of 2022 to assess the use of sotrovimab in uninfected immunocompromised patients to determine whether sotrovimab can prevent symptomatic COVID-19 infection. One trial is a platform trial and one trial is a company sponsored trial, COMET-STAR. The primary endpoint for both trials is incidence of symptomatic PCR-confirmed COVID-19. The analysis of the primary endpoint of COMET-STAR will be event driven, and is still expected to be as early as the second half of 2022.

 

  •  

The Company still expects initial data from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) Trial, which is evaluating sotrovimab among patients hospitalized with COVID-19 in the United Kingdom, in the second half of 2022.

 

  •  

The Company still expects additional data from the United Kingdom’s National Health Service-supported AGILE initiative evaluating VIR-7832, an investigational dual-action SARS-CoV-2 monoclonal antibody, in a Phase 1b/2a trial of adults with mild-to-moderate COVID-19 in the first half of 2022.

Forward-Looking Statements

This Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “expect,” “will,” “plan,” “potential,” “aim,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this Form 8-K. Forward-looking statements contained in this Form 8-K include, but are not limited to, statements regarding the ability of sotrovimab to treat and/or prevent COVID-19, the terms and limitations of use of the EUA for sotrovimab, the Company’s collaboration with GSK, near-term collaboration revenue related to agreements for doses of sotrovimab, the timing and expected number of therapeutic doses that the Company will be able to supply to patients, planned discussions with global regulatory agencies as well as planned submissions and filings and the timing thereof, the timing of availability of data, program updates, data disclosures and publications related to sotrovimab and VIR-7832, the ability of sotrovimab to maintain activity against the Omicron BA.2 subvariant, and the clinical development program for sotrovimab and VIR-7832. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, actual timing and content of submissions to and decisions made by the regulatory authorities regarding sotrovimab; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of sotrovimab; challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, successful development and/or commercialization of alternative product candidates by the Company’s competitors, changes in expected or existing competition, delays in or disruptions to the Company’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this Form 8-K are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits    

 

Exhibit
No.

   

Description

99.1    Press Release of the Company, dated March 25, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      VIR BIOTECHNOLOGY, INC.
Date: March 25, 2022     By:  

/s/ Howard Horn

      Howard Horn
Chief Financial Officer and Secretary
 EX-99.1 2 d262323dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    LOGO

US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant

SAN FRANCISCO, March 25, 2022 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody. The FDA has determined that, based on the totality of available evidence, including new live virus data generated by Vir, it is unlikely that the sotrovimab 500 mg dose will be effective against the Omicron BA.2 variant. GSK and Vir are preparing a package of data in support of a higher dose of sotrovimab for the Omicron BA.2 subvariant and will be sharing these data with regulatory and health authorities around the world for discussion.

The FDA has updated its website to exclude sotrovimab use in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information, including variant susceptibility to these drugs and regional variant frequency (HHS regions 1 and 2). The FDA will continue to monitor the prevalence of circulating variants and update its website accordingly.

In connection with this announcement, Vir has filed a Current Report on Form 8-K, which can be found at www.sec.gov.

About sotrovimab

Sotrovimab is an investigational SARS-CoV-2 neutralizing monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor, Inc.’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.

About global access to sotrovimab

Sotrovimab is authorized for emergency use in the United States and has been granted a marketing authorization in the European Union (EU), conditional marketing authorization in the UK, provisional marketing authorization in Australia, and conditional marketing authorization in Saudi Arabia. It has also been approved via Japan’s Special Approval for Emergency Pathway. Temporary authorizations for sotrovimab have also been granted in several other countries.

Sotrovimab is supplied in several countries worldwide, including through national agreements in the US, UK, Japan, Australia, Canada, Singapore, Switzerland and the United Arab Emirates. Vir and GlaxoSmithKline are also supplying sotrovimab to participating Member States of the EU through a Joint Procurement Agreement with the European Commission. Additional agreements are yet to be disclosed due to confidentiality or regulatory requirements.

Sotrovimab in the United States

The following is a summary of information for sotrovimab. Healthcare providers in the US should review the Fact Sheets for information about the authorized use of sotrovimab and mandatory requirements of the Emergency Use Authorization (EUA). Please see the Food and Drug Administration (FDA) Letter of Authorization, full Fact Sheet for Healthcare Providers and full Fact Sheet for Patients, Parents, and Caregivers.

Sotrovimab has been authorized by the FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.

Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Authorized use

The FDA has issued an EUA to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Limitations of authorized use

 

  •  

Sotrovimab is not authorized for treatment of mild to moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information including variant susceptibility to these drugs and regional variant frequency.

 

  •  

FDA’s determination and any updates will be available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs.

Sotrovimab is not authorized for use in adult or pediatric patients who:

 

  •  

are hospitalized due to COVID-19, OR

 

  •  

require oxygen therapy and/or respiratory support due to COVID-19, OR

 

  •  

require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 in those on chronic oxygen.

Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID-19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

Important Safety Information

CONTRAINDICATIONS

Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.

WARNINGS AND PRECAUTIONS

There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.

Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.

Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life-threatening.

Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (e.g., pre-syncope, syncope), dizziness and diaphoresis.

If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care. Clinically monitor patients for at least 1 hour after completion of the infusion for signs and symptoms of hypersensitivity. Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.

Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration

Clinical worsening of COVID-19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, tachycardia, bradycardia), fatigue and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID-19.

Limitations of Benefit and Potential for Risk in Patients with Severe COVID-19

Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID-19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID-19, OR who require oxygen therapy due to COVID-19 OR who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

ADVERSE EVENTS

Infusion-related reactions, including immediate hypersensitivity reactions, were observed in subjects treated with sotrovimab in COMET-ICE (1%) and in COMET-TAIL (<1%). Events reported within 24 hours of study treatment were pyrexia, chills, dizziness, dyspnea, pruritus, rash, and infusion-related reactions; all events were Grade 1 (mild) or Grade 2 (moderate).

Hypersensitivity adverse reactions were observed in 2% of patients treated with sotrovimab in COMET-ICE and in <1% of subjects treated with sotrovimab in COMET-TAIL. All were Grade 1 (mild) or Grade 2 (moderate). One reaction led to temporary pausing of the infusion.

The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate).

USE IN SPECIFIC POPULATIONS

Pregnancy

A pregnancy exposure registry monitors pregnancy outcomes in women exposed to sotrovimab during pregnancy. To enroll, go to https://covid-pr.pregistry.com/ or call 1-800-616-3791 to obtain information about the registry.

There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus. There are maternal and fetal risks associated with untreated COVID-19 in pregnancy.

Lactation

There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

About the GSK and Vir Collaboration

In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.

GSK Commitment to Tackling COVID-19

GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to the Company’s vaccine candidates in development with partner organisations.

GSK is collaborating with several organisations on COVID-19 vaccines by providing access to its adjuvant technology. The Company is working with Sanofi SA, Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.

GSK is also working with mRNA specialist CureVac NV to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.

GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.

Vir’s Commitment to COVID-19

Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in pre-clinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.

About GSK

GSK is a science-led global healthcare company. For further information please visit www.gsk.com/aboutus.

About Vir Biotechnology

Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. We routinely post information that may be important to investors on our website at www.vir.bio.

GSK Cautionary Statement Regarding Forward-Looking Statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company’s Annual Report on Form 20-F for 2021 and any impacts of the COVID-19 pandemic.

Vir Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the ability of sotrovimab to treat and/or prevent COVID-19, Vir’s collaboration with GlaxoSmithKline, planned discussions with global regulatory agencies, the timing of availability of pre-clinical data, data disclosures and publications related to sotrovimab. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy

data observed during pre-clinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, successful development and/or commercialization of alternative product candidates by Vir’s competitors, changes in expected or existing competition, delays in or disruptions to Vir’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the US Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

Vir Biotechnology Contacts:

Investors

Heather Rowe Armstrong

VP, Investor Relations

harmstrong@vir.bio

+1 415 915 4228

Media

Cara Miller

VP, Corporate Communications

cmiller@vir.bio

+1 415 941 6746

 

GSK inquiries:

        

Media inquiries:

   

Tim Foley

  

+44 (0) 20 8047 5502

   

(London)

  

Madeleine Breckon

  

+44 (0) 20 8047 5502

   

(London)

  

Kathleen Quinn

  

+1 202 603 5003

   

(Washington DC)

  

Lyndsay Meyer

  

+1 202 302 4595

   

(Washington DC)

Analyst/Investor inquiries:

   

Nick Stone

  

+44 (0) 7717 618834

   

(London)

  

Sonya Ghobrial

  

+44 (0) 7392 784784

   

(Consumer)

  

James Dodwell

  

+44 (0) 20 8047 2406

   

(London)

  

Mick Readey

  

+44 (0) 7990 339653

   

(London)

  

Josh Williams

  

+44 (0) 7385 415719

   

(London)

  

Jeff McLaughlin

  

+1 215 751 7002

   

(Philadelphia)

  

Frannie DeFranco

  

+1 215 751 4855

   

(Philadelphia)

 EX-101.SCH 3 vir-20220325.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 vir-20220325_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 vir-20220325_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g262323g19v43.jpg GRAPHIC begin 644 g262323g19v43.jpg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end GRAPHIC 7 g262323g59r55.jpg GRAPHIC begin 644 g262323g59r55.jpg M_]C_X 02D9)1@ ! 0$ ;@!N #_X0!:17AI9@ 34T *@ @ !0,! 4 M ! 2@,# $ ! %$0 $ ! 0 %$1 0 ! 0ZE$2 M 0 ! 0Z@ 8:@ "QC__; $, " 8&!P8%" <'!PD)" H,% T, M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_ !$( #< 70,!(@ "$0$#$0'_ MQ ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " 0,# @0# M!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*" M"0H6%Q@9&B4F)R@I*C0U-C+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$! M 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G< M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J" M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@ , P$ A$#$0 _ /;;KQ!I M%E<-;W6I6T,R_>1Y "*LPZC9W-J+J"YBD@/216ROYUY_\5?!G]L:=_;%E%F^ MM5_>!1S)'_B*X?X9>+$TJ_.C:@__ !+[P[1N/$;G^AI.]M-P5KZGN_\ :-G_ M ,_,7_?5217=O,VV*9';KA3FN&U&Q:PNVB/*GE&]16AX9_Y"+_[E>-2S.K+$ M*C.-M;'H3PD%2]I&5S:;Q-H:3&%M5M!(&VE3*,@^E3WNLZ;IKJE[?06[.,J) M' R*^9=4 _X3*YX_Y?C_ .AUW/QM_P"0SI?_ %P;^8KV['GGL2ZOISV#7ZWL M)M%^],'&T=NM5/\ A*] _P"@Q9_]_17F.E_\D"U#_>;_ -&"O.?#WAV]\3:E M]@L/+\[87_>-@8%%@/I3_A*] _Z#%G_W]%7K34K*^&;2[AG_ .N;@UX/_P * M=\3^EG_W]/\ A7.W^F:_X*U./SQ-9S_>CDC;Y7QZ$=?I18#ZDHKD/AYXM;Q5 MH6^XP+VW.R;'\7HWXUU](!" P((R#U!KY[^)O@\^'M9-]:(1I]VQ9<#B-^X_ MPKZ%K-UW1;77]'N-.NUS'*N W=6[$?2@#S_P-XB7Q=X=.EWCC^UK%?D9CS*G M8_7L?P-=+X:4IJDBL,,$((->%,NI^!/%V.4NK.3(/:1?\"*^@/#EY9Z[%#KE MBPV3QXE3/*OW%<&(P?-B(5X[IZG33KVI2IOJ?/.J?\CE<_\ 7\?_ $.NY^-O M_(9TO_K@W\Q7#:I_R.5S_P!?Q_\ 0Z[GXV_\AG2_^N#?S%>@:ETGE'ODYS^E9'B;XF>(O#6N3Z=<:=:D*!1 MQ&_^!IH#D-2(;QC<,I!!OB01_OUW7QM_Y#.E_P#7!OYBO-;,DZA;DG)\U?YB MO2OC;_R&=+_ZX-_,4Q%G2_\ D@6H?5O_ $8*Q_@W_P CH_\ U[/_ $K8TO\ MY(%J'U;_ -&"L?X-_P#(Z/\ ]>S_ -*0STGXD>$!XET-IK9!_:%J"\6.KCNO M^%>9_"WQ#9Z-K[6&HV\(6Z;:D[H-T4G3&?0]/K7T#7A?Q8\''2]1_MZQCQ:W M+?OE4?ZN3U^A_G0![H.E%>>_##QI_;VF#3;V3.H6JX!)YD3L?K7H5( HHHH M*IZIIEKK&FS6%Y&'@F7:P_J/>BB@#BHO@]X;BE217O-R,&&9?2MKQ-X%TGQ7 M%"B^6^.#110 ^#P5I=OX3F\.(T_V*4DL2_SZ/X8U(W M]@UP9BA3]X^1@T44 =9534M.MM6T^:QO(Q)!,I5U-%% ')Z5\+M$T;4H;^RG 1O4GB;*GS>#['VKMZ** /_]D! end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Mar. 25, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001706431
Document Type 8-K
Document Period End Date Mar. 25, 2022
Entity Registrant Name Vir Biotechnology, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39083
Entity Tax Identification Number 81-2730369
Entity Address, Address Line One 499 Illinois Street
Entity Address, Address Line Two Suite 500
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94158
City Area Code (415)
Local Phone Number 906-4324
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value
Trading Symbol VIR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 d262323d8k_htm.xml IDEA: XBRL DOCUMENT 0001706431 2022-03-25 2022-03-25 false 0001706431 8-K 2022-03-25 Vir Biotechnology, Inc. DE 001-39083 81-2730369 499 Illinois Street Suite 500 San Francisco CA 94158 (415) 906-4324 false false false false Common Stock, $0.0001 par value VIR NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $&!>50'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !!@7E4"-C5K^T K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)TW10^CVLN))07!!\1:2V=U@\X=DI-VWMXV[740?P&-F?OGF M&YA.1ZE#PN<4(B:RF&\F-_@L==RP(U&4 %D?T:E5297)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M08%Y5%*?3\Q+! XA !@ !X;"]W;W)K&V'1KCIG>!,O6>?WHZ/B5E.%6FQ>[X=R1MU0J>]/:.)=]# (;;WC*[)7. MN((G*VU2YJ!IUH'-#&=)$93*@(9A+TB94*W1L+@W,Z.ASIT4BL\,L7F:,K.[ MY5)O;UI1Z_W&DUAOG+\1C(896_,Y=[]G,P.MH%1)1,J5%5H1PU!C,DED^T?*;2-SFIM5OD82O6"[=D][^R@\#*@!C+6WQEVSW?3MA MB\2Y=3H]! -!*M3^E[T=$G$4T*8G N@A@!;<^Q<5E'?,L='0Z"TQOC>H^8MB MJ$4TP GE9V7N##P5$.=&=SK.(^6$VY&IVL\V9&T8.'B)[QK$!\'; MO2 ](?B%F2M"NQ>$AI3^.SP MA*0EH"TT&N?T)OH5V[(G^.E=0:F\"]$LEU* MM@O)S@G),0PX*0;](-FZ;HAX_(I)RQ&.3LG1074.Z9X B6$2TI[P-_*)[^J( M<*4P#*/KL-=I1PA6M\3JHF)E22QV&:]CPA2&W0CL>;Y26>KV[ M@!J(KQ#"?DG8/X<0U+3)M"D^93)WD#\RT3F4&U2=3FJ1<>&[>X1N4-(-SJ%[ M$)*3QSQ=)^TTWP-DOWH MDEZWPW9O@!$>V71T#N$X20RW]N+]@GR&?N2KJIW*!LG.8$"F$NYJ8:$X#"PA M&&IEV!']_ZB+K:Y%Q27GN8#2[88A!EC9?X3[]_> $]_2ABSTMG[!P^7F3)$' ML(%8V%AC@-6Z$)VU,)2 ^R\7"&=&OPH5U\\VKCD98VC5VA#A[OX]VDQ;!VO7 M'R([Z2@-BH-.U.UC;-62$>%.7\SC&/:FIU%P@9\ Y6<,I5HA(MS:/^L8LC+; M:(597(/((.Q==MJT@Q%5*T*$._&BU"E#&%^GA\(7M-T"P3X3-Y]?5JG[^ M&O0:R2KWI[A5_X=L:FT.9(V N&PCX-$FO<&@>9P;__E%=$D6PLG:SZ]!Q(^P MV*?H^.6"_!A>^6TMR9@AKTSF*&CE_10WZX5AB2^X^2Y=ZMIR:Q!XGCYA()7' M4]R/RXS=O\4;IM;\Y":R0>AQ/+\;_X8Q5>9.SS+W^Y2;M4_2+Z#@-K[R,J9J MCR4-@B<++#@ZL?K3/VS2X8V62+X"H?#J&G3-_D"];SB=%8?8I79P)"XN-YQ! M\?L.\'RE81]]:/AS52?H!OPL0( .(, - M >&PO9KEMWDOSAR+DCO9*ZW="C M<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+ M#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\ M0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9 M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I: M*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#S MGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[ MBK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1 MS;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG M_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P M%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/ MK O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( $&!>527 MBKL

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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d262323d8k.htm d262323dex991.htm vir-20220325.xsd vir-20220325_lab.xml vir-20220325_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d262323d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d262323d8k.htm" ] }, "labelLink": { "local": [ "vir-20220325_lab.xml" ] }, "presentationLink": { "local": [ "vir-20220325_pre.xml" ] }, "schema": { "local": [ "vir-20220325.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vir", "nsuri": "http://www.vir.bio/20220325", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d262323d8k.htm", "contextRef": "duration_2022-03-25_to_2022-03-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d262323d8k.htm", "contextRef": "duration_2022-03-25_to_2022-03-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vir.bio//20220325/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-085150-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-085150-xbrl.zip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end